A new oral anticoagulant: the 50-year challenge
暂无分享,去创建一个
Ingemar Nilsson | Ulf Bredberg | David Gustafsson | U. Bredberg | I. Nilsson | U. Eriksson | Ruth Bylund | Thomas Antonsson | Jan-Erik Nyström | Ulf Eriksson | Ann-Catrine Teger-Nilsson | D. Gustafsson | A. Teger‐Nilsson | T. Antonsson | J. Nyström | R. Bylund
[1] H Oschkinat,et al. The interaction of thrombin with fibrinogen. A structural basis for its specificity. , 1992, European journal of biochemistry.
[2] Robert Huber,et al. The refined 1.9 A crystal structure of human alpha‐thrombin: interaction with D‐Phe‐Pro‐Arg chloromethylketone and significance of the Tyr‐Pro‐Pro‐Trp insertion segment. , 1989 .
[3] J. Deinum,et al. The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis , 1997, Thrombosis and Haemostasis.
[4] E. Shaw,et al. D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin. , 1979, Thrombosis research.
[5] S. Carlsson,et al. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. , 2002, Thrombosis research.
[6] R. Huber,et al. The refined 1.9 A crystal structure of human alpha‐thrombin: interaction with D‐Phe‐Pro‐Arg chloromethylketone and significance of the Tyr‐Pro‐Pro‐Trp insertion segment. , 1989, The EMBO journal.
[7] S. Olsson,et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.
[8] V. Feigin,et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century , 2003, The Lancet Neurology.
[9] M. Wolzt,et al. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects , 2003, European Journal of Clinical Pharmacology.
[10] Ulf Bredberg,et al. Animal pharmacokinetics of inogatran, a low‐molecular‐weight thrombin inhibitor with potential use as an antithrombotic drug , 1998, Biopharmaceutics & drug disposition.
[11] D. Gustafsson. Oral direct thrombin inhibitors in clinical development , 2003, Journal of internal medicine.
[12] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[13] Jing Fang,et al. Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. , 2002, The American journal of medicine.
[14] B. Eriksson,et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement , 2003, Thrombosis and Haemostasis.
[15] J. Lehmann. HYPO-PROTHROMBINEMIA PRODUCED BY 3,3-METHYLENEBIS (4-HYDROXYCOUMARIN) AND ITS USE IN THE TREATMENT OF THROMBOSIS. , 1942, Science.
[16] W. Weaver,et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.
[17] A. Turpie,et al. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. , 2001, The New England journal of medicine.
[18] L. Johansson,et al. No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers , 2003, Clinical pharmacokinetics.
[19] Per Artursson,et al. Selective Paracellular Permeability in Two Models of Intestinal Absorption: Cultured Monolayers of Human Intestinal Epithelial Cells and Rat Intestinal Segments , 1993, Pharmaceutical Research.
[20] R. Kikumoto,et al. A Synthetic Thrombin Inhibitor Taking Extremely Active Stereo-Structure , 1979, Thrombosis and Haemostasis.
[21] K. P. Link. The Discovery of Dicumarol and Its Sequels , 1959, Circulation.
[22] K. P. Link,et al. Studies on the Hemorrhagic Sweet Clover Disease IX. The Effect of Diet and Vitamin K on the Hypopro-Thrombinemia Induced by 3,3???-Methylenebis (4-Hydroxycoumarin) in the RatOne Figure , 1942 .
[23] S. Schulman,et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.
[24] B. Eriksson,et al. A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I , 2002, Thrombosis and Haemostasis.
[25] T. Andersson,et al. Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions , 2003, Clinical pharmacokinetics.
[26] F. Markwardt. The development of hirudin as an antithrombotic drug. , 1994, Thrombosis research.
[27] T. Steinmetzer,et al. Advances in the development of thrombin inhibitors , 2001, Expert opinion on investigational drugs.
[28] D. W. Murray,et al. Heparin and the thrombosis of veins following injury , 1937 .
[29] E. Di Cera. Thrombin interactions. , 2003, Chest.
[30] K. P. Link,et al. STUDIES ON THE HEMORRHAGIC SWEET CLOVER DISEASE IV. THE ISOLATION AND CRYSTALLIZATION OF THE HEMORRHAGIC AGENT , 1941 .
[31] N. W. Barker,et al. A PREPARATION FROM SPOILED SWEET CLOVER: [3,3′-Methylene-Bis-(4-Hydroxycoumarin)] Which Prolongs Coagulation and Prothrombin Time of the Blood: A Clinical Study , 1942 .
[32] K. Mann,et al. Thrombin formation. , 2003, Chest.
[33] F. R. Bettelheim. The clotting of fibrinogen. II. Fractionation of peptide material liberated. , 1956, Biochimica et biophysica acta.
[34] S. Carlsson,et al. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. , 1999, Thrombosis research.
[35] H. Diener,et al. Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study Design and Baseline Data , 2003, Cerebrovascular Diseases.
[36] J. Deinum,et al. Design and synthesis of thrombin inhibitors , 1995, Letters in Peptide Science.
[37] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.
[38] H. Scheraga,et al. High-resolution NMR studies of fibrinogen-like peptides in solution: structure of a thrombin-bound peptide corresponding to residues 7-16 of the A alpha chain of human fibrinogen. , 1989, Biochemistry.
[39] L. Lapidus,et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. , 2002, Thrombosis research.
[40] J. Westwick,et al. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. , 1982, British medical journal.
[41] U. Eriksson,et al. No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran , 2003, Clinical pharmacokinetics.
[42] L. Johansson,et al. Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.
[43] David Gustafsson,et al. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. , 2003, Thrombosis research.
[44] J. Lehmann. HYPOPROTHROMBINÆMIA PRODUCED BY METHYLENE-BIS-(HYDROXYCOUMARIN): ITS USE IN THROMBOSIS , 1942 .
[45] S. Pehrsson,et al. Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes , 1998, Thrombosis and Haemostasis.
[46] S. Bajusz,et al. Inhibition of thrombin and trypsin by tripeptide aldehydes. , 2009, International journal of peptide and protein research.
[47] U. Bredberg,et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[48] H. White,et al. Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions , 2002, Expert opinion on pharmacotherapy.
[49] M. Blombäck,et al. Synthetic peptides with anticoagulant and vasodilating activity. , 1969, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[50] H. Mulec,et al. Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran , 2003, Clinical pharmacokinetics.
[51] B. Eriksson,et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study , 2003, Journal of thrombosis and haemostasis : JTH.
[52] U. Eriksson,et al. No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.
[53] R. Kikumoto,et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. , 1981, Biochemical and biophysical research communications.
[54] U. Eriksson,et al. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. , 1997, Thrombosis research.
[55] A Abrahamsson,et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.
[56] C. Mathew,et al. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. , 2003, Blood.
[57] M. Wolzt,et al. Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects , 2002, Thrombosis and Haemostasis.
[58] Ulf Bredberg,et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects , 2003, European Journal of Clinical Pharmacology.
[59] J. Walenga. An Overview of the Direct Thrombin Inhibitor Argatroban , 2003, Pathophysiology of Haemostasis and Thrombosis.
[60] Miller,et al. CLINICAL STUDY The , 2022 .
[61] J. Hirsh,et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.
[62] C. Colwell,et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. , 2003, The New England journal of medicine.